Hormonal Therapy in the Elderly Prostate Cancer Patient

Pfitzenmaier, Jesco; Altwein, Jens E.

doi:10.3238/arztebl.2009.0242

Cited by 6 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients with PCa underwent different treatment modalities, which might have had an influence on the lipid parameters. After hormonal therapy (LHRH analog + antiandrogen bicalutamide or flutamide = maximal androgen blockade [MAB]), prostate cells are deprived of androgen, which decreases proliferation and progression of prostate cancer cells (Pfitzenmaier & Altwein, 2009). Certain studies point to a continuous ADT treatment in older men as the cause of an increased risk of diabetes and fragility fracture but not acute myocardial infarction or sudden cardiac death (Alibhai et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Lipid Status During Combined Treatment in Prostate Cancer Patients

et al. 2019

View full text Add to dashboard Cite

The aim of this study was to provide a specific review of current medical literature regarding the lipid profile during prostate carcinoma (PCa) treatment. The main aim was to analyze the results presented by different authors and to find a commonality in the changes occurring during the treatment—hormonotherapy. The levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured before and after the follow-up treatment. The manuscripts reviewed came from the period between 2008 and 2016. The size of the studies ranged from 16 participants to 310. The mean age was from 65 to 74 years in all studies. The Q test was used to attain all lipid parameters and to specify heterogeneity ( p < .0001). After 12 months of androgen deprivation therapy (ADT), the patients had a significantly higher level serum TC and TG.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid Status During Combined Treatment in Prostate Cancer Patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Years of research have provided a wide number of available therapeutic strategies to tackle this pathology, including surgery, chemotherapy, radiotherapy and/or androgen‐deprivation therapy (ADT), which together with the capacity of early detection due to the implementation of PSA screening, have permitted to reach almost 100% survival after 5 years when the tumor is localized . Unfortunately, these therapeutic approaches are associated with serious side effects . In addition, there is a lack of tools that can accurately guide treatment selection, which complicates options and choices for clinicians and patients .…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6] Unfortunately, these therapeutic approaches are associated with serious side effects. 7 In addition, there is a lack of tools that can accurately guide treatment selection, which complicates options and choices for clinicians and patients. 8 Altogether, these facts demonstrate the necessity of identifying and characterizing novel therapeutic targets that can become useful for the development of new treatment and/or management strategies.…”

Section: Introductionmentioning

confidence: 99%

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Antagoniści hamują aktywność przysadki przez blokowanie receptorów dla GnRH. W celu hamowania aktywacji androgenów stosuje się antyandrogeny steroidowe (octanu cyproteronu) oraz niesteroidowe (flutamid, bikalutamid, nilutamid) [28]. Leki blokują wiązanie testosteronu i dihydrotestosteronu do receptorów androgenowych.…”

Section: Wpływ Leczenia Onkologicznego Na Układ Kostnyunclassified

“…Leki blokują wiązanie testosteronu i dihydrotestosteronu do receptorów androgenowych. Dowiedziono, że stosowanie terapii antyandrogennej przyczynia się do obniżenia stężenia androgenów o 90% [28]. Wśród mężczyzn leczonych analogami GnRH przez okres 1,5 roku zaobserwowano spadek BMD w okolicach szyjki kości udowej i w odcinku lędźwiowym kręgosłupa.…”

Section: Wpływ Leczenia Onkologicznego Na Układ Kostnyunclassified

Effects of oncological therapy on bone disorders

Wysoczańska¹,

Ślęzak²,

Barg³

2017

Pediatr Endocrino Diabetes Metab

View full text Add to dashboard Cite

Due to increasing incidence of cancer disease and the searching for new, aggressive methods of therapy, more attention is focusing on applied treatment consequences. The specificity of oncological drugs allows to destroy cancer cells, simultaneously destroying and disrupting the functioning of healthy tissues. Side effects concern infertility, urolotoxicity, nephrotoxicity, neurotoxicity or bone marrow suppression. Chemotherapy can also be affected on physiological function of movement system and the skeleton construction. Mineral status disorders and skeletal changes lead to secondary forms of osteopenia and osteoporosis and refer oncological patients of any age. The main cause of these conditions is an imbalance between osteoclast and osteoblast activity, occurring as a result of drug interactions, parathyroid hormone-like proteins or interleukins. In addition to the direct effect on bone tissue, disorders in its construction and metabolism are also manifested as a consequence of hypogonadism. The sexual hormones at normal level can inhibit process of bone destruction, increase parathormone level, stimulate active vitamin D3 formation and intestinal calcium absorption. The deficiency of estrogens and androgens indirectly leads to disorder of bone metabolism and homeostasis. Symptoms such as musculoskeletal pain and fractures appear in the late stage of degeneration. Moreover, the appropriate selection of therapy and dosage, compatible with the patient's age and condition are crucial for treatment. Early bone loss should be prevented by supplementing with calcium, vitamin D3, hormone replacement therapy or bisphosphonates. The physical activity and proper diet are important as well. The aim of the study was to characterize the most common oncological treatment regimens, considering the long-term side effect of applied therapy and its influence on the skeletal mineralization and trace element profile. Based on the mechanism of drug action, the disorders observed after pharmacotherapy were described. The processes leading to bone's composition changes were discussed and prevention of their occurrence were estimated.

show abstract

Hormonal Therapy in the Elderly Prostate Cancer Patient

Cited by 6 publications

References 32 publications

Lipid Status During Combined Treatment in Prostate Cancer Patients

Lipid Status During Combined Treatment in Prostate Cancer Patients

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

Effects of oncological therapy on bone disorders

Contact Info

Product

Resources

About